Schizophrenic disorder treatment using combination therapy
AssigneeCambridge Cognition Limited
InventorsKiri Granger, Jennifer Barnett
Life of this patent
Estimating the term…
Abstract
The present specification disclose a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in treating a schizophrenic disorder as well as methods of treating a schizophrenic disorder by administering a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity.
Claims21
A method of treating a schizophrenic disorder by administering a combination therapy comprising Tropisetron and Varenicline.
Dependencies are inferred from the claim text.